Make a note!
$Syros Pharmaceuticals(SYRS.US$ The company is expected to release crucial data from the SELECT-MDS-1 Phase 3 trial for newly diagnosed high-risk MDS patients by the fourth quarter of 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
